Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 26 Issue 7, July 2008

Colored scanning electron micrograph of a resin cast of blood vessels that supply the small intestine. Benny et al. show that an oral formulation of an anti-angiogenic drug is absorbed by the intestine, inhibits tumor growth and prevents liver metastasis (p 799). Credit: Susumu Nishinaga and Photo Researchers, Inc.

Volume 26 Issue 7

Subscribe

Editorial

  • With follow-on biologics essentially dead in the water in the US, the decision of the world's largest generics manufacturer to invest in a platform for enhancing protein pharmacokinetics could pay dividends.

    Editorial

    Advertisement

  • Moves to clamp down on companies offering direct-to-consumer genetic tests are out of step with personal genomics and its potential to empower individuals' role in their own healthcare.

    Editorial
Top of page ⤴

News

Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Although dendrimers have not yet taken the drug industry by storm, biomedical research and industrial applications of these tiny, highly branched molecules continue to grow. Vivien Marx reports.

    • Vivien Marx
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics—the core identity of the biotech industry and its products is at stake.

    • Ronald A Rader
    Commentary
Top of page ⤴

Feature

  • Record profits and financing in the public biotech sector may be unsustainable in the coming years as economies falter.

    • Stacy Lawrence
    • Riku Lähteenmäki
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

Top of page ⤴

Analysis

  • An inability to estimate absolute DNA methylation levels has slowed progress in understanding the role of this epigenetic modification in health and disease. Down et al. describe an algorithm for analyzing methylated DNA immunoprecipitation profiles generated using either high-throughput sequencing or oligonucleotide arrays.

    • Thomas A Down
    • Vardhman K Rakyan
    • Stephan Beck
    Analysis
Top of page ⤴

Perspective

Top of page ⤴

Brief Communication

  • Existing methods for reprogramming somatic cells to 'induced pluripotent stem cells' are inefficient, with only a small fraction of the starting cell population becoming pluripotent. Working with mouse embryonic fibroblasts, Hunagfu et al. increase reprogramming efficiency by treatment with DNA methyltransferase and histone deacetylase inhibitors.

    • Danwei Huangfu
    • René Maehr
    • Douglas A Melton
    Brief Communication
Top of page ⤴

Article

Top of page ⤴

Letter

  • Microarray platforms usually rely on fluorescence detection. Clack et al. present an equally sensitive, label-free technique that electrostatically detects DNA or RNA hybridization after randomly dispersing charged microspheres onto the microarray surface.

    • Nathan G Clack
    • Khalid Salaita
    • Jay T Groves
    Letter
Top of page ⤴

Corrigendum

Top of page ⤴

Erratum

Top of page ⤴

Careers and Recruitment

  • Expert tips for acquirers and acquirees to get through a difficult post-merger integration.

    • Mari Paul
    Careers and Recruitment
Top of page ⤴

People

Top of page ⤴

Search

Advanced search

Quick links